The US Patent and Trademark Office (USPTO) has issued a patent to CyDex Pharmaceuticals (CyDex) entitled ‘Sulfoalkyl Ether Cyclodextrin Compositions.’ The patent, along with other previously issued technology patents, is expected to provide broad protection for CyDex’s Captisol technology until 2029.
Reportedly, the patent (US Patent No 7635773) covers a manufacturing process for producing ultra modified cyclodextrins, and specifically the beta cyclodextrin sulfobutyl ether sodium salt product known as Captisol.
Captisol is CyDex’s proven enabling drug delivery technology that aids in the solubilisation, stabilisation and taste masking of active pharmaceutical ingredients.
Theron Odlaug, president and CEO of CyDex, said: “Receiving this new patent is an important achievement as we continue to license Captisol technology and develop our own products that target unmet needs in hospital intravenous therapy.
“Captisol removes many impurities and degradants so that the composition can be used to increase the stability of highly sensitive active pharmaceutical ingredients. Together with the morphology patent we received earlier this month, this patent ultimately provides broader protection for our clients using Captisol and provides them with critical life-cycle management for their products.”